Barclays Maintains Overweight on Globus Medical, Raises Price Target to $77
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Matt Miksic maintains an Overweight rating on Globus Medical (NYSE:GMED) and raises the price target from $75 to $77.
August 07, 2023 | 11:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintains an Overweight rating on Globus Medical and raises the price target from $75 to $77, indicating a positive outlook for the stock.
The raised price target by Barclays indicates their belief in the company's potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100